Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial

Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial

Abstract Background Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular lea...

Full description

Bibliographic Details
Main Authors: Geoff Bellingan, David Brealey, Jordi Mancebo, Alain Mercat, Nicolò Patroniti, Ville Pettilä, Michael Quintel, Jean-Louis Vincent, Mikael Maksimow, Markku Jalkanen, Ilse Piippo, V. Marco Ranieri
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Trials
Subjects:
Interferon
ARDS
Vascular leakage
CD73
Online Access:http://link.springer.com/article/10.1186/s13063-017-2234-7

Internet

http://link.springer.com/article/10.1186/s13063-017-2234-7

Similar Items